Correspondence lukas.sommer@anatom.uzh.ch (L.S.), onur.boyman@uzh.ch (O.B.) In Brief Zingg et al. investigate the mechanisms of adaptive resistance to tumor immunotherapy. They find that intratumoral TNF-a production and T cell accumulation promote Ezh2 upregulation in melanoma cells, resulting in loss of immunogenicity and antigen presentation. Ezh2 inactivation reverses these effects and synergizes with anti-CTLA-4 and IL-2 immunotherapies.
INTRODUCTION
The immune system plays a dual role during cancer elimination versus progression. Immune cells recognize and eliminate malignant cells via a process termed cancer immunosurveillance, which relies on interferon-g (IFN-g) and tumor necrosis factor a (TNF-a) production by CD4 + and CD8 + T cells (Schreiber et al., 2011) . However, these immune mechanisms also pressurize tumor cells to initiate a dedifferentiation program associated with loss of dominant tumor antigens and silencing of the antigen-processing and presenting machinery (Hö lzel and T€ uting, 2016; Schreiber et al., 2011) . In addition to these cell-intrinsic modifications, extrinsic signals can contribute to cancer cell resistance. Thus, various factors are able to promote an immunosuppressive tumor microenvironment, including certain cytokines, chemokines, enzymes, and negative costimulatory molecules, as well as CD4 + CD25 + forkhead boxP3 (FoxP3) + regulatory T (Treg) cells and CD11b + Gr-1 + myeloid-derived suppressor cells (MDSCs). Anti-tumor effector T cells facing antigen persistence upregulate PD-1 and become exhausted when encountering PD-L1-expressing tumor cells, thus progressively losing their effector functions, including IFN-g production (Wherry and Kurachi, 2015) . Accordingly, immune checkpoint molecules, including PD-1 and its ligand, PD-L1, contribute to an immunosuppressive tumor microenvironment (Schreiber et al., 2011; Topalian et al., 2015; Tumeh et al., 2014) . Therapies targeting PD-1, PD-L1, and CTLA-4, also termed immune checkpoint inhibitors, increase the anti-tumor T cell response and have shown some considerable anti-tumor effects in patients with metastatic cancer, particularly melanoma (Larkin et al., 2015; Topalian et al., 2015) . However, despite these treatments, many cancer patients experience progression of their disease, probably indicating that tumor cells resort to resistance strategies when facing heightened immune pressure. The molecular pathways determining tumor escape from immunotherapy remain poorly understood.
To study the molecular mechanisms of resistance to anticancer treatment, we chose to use two different modes of immunotherapy in three mouse models of melanoma. Interleukin-2 (IL-2) immunotherapy is approved for metastatic melanoma (Rosenberg, 2014) and has the advantage of stimulating anticancer T cell responses independently of PD-1, PD-L1, and CTLA-4 expression. We and others have been studying IL-2 and improved IL-2 formulations, including IL-2/anti-IL-2 monoclonal antibody (mAb) complexes (IL-2cx), in various preclinical and clinical settings of metastatic melanoma . In preclinical studies, IL-2cx, but not free IL-2 or anti-IL-2 mAb (Boyman et al., 2006) , exerted vigorous anti-tumor immune responses against syngeneic B16-F10 melanoma and other cancers in mice (Arenas-Ramirez et al., 2016; Krieg et al., 2010; Levin et al., 2012) . However, despite continuous treatment with IL-2cx, B16-F10 melanoma nodules ultimately grew out in most animals, suggesting subversion of immune-mediated tumor control.
In human melanoma, genetic determinants of immune resistance remain elusive, whereas transcriptomic alterations appear to be a major feature of immune evasion (Hugo et al., 2016; Van Allen et al., 2015) . We thus hypothesized that immune pressureinduced epigenetic rewiring of the transcriptional landscape might drive immune resistance in melanoma cells. The polycomb repressive complex 2 (PRC2) is a prominent chromatin-remodeling complex that mediates transcriptional repression via trimethylation of lysine 27 in histone 3 (H3K27me3). PRC2 consists of embryonic ectoderm development (EED), suppressor of zeste 12 (SUZ12), and the histone methyltransferase unit EZH2, among others (Kim and Roberts, 2016) . Here, we show that Ezh2 controls crucial melanoma cell-intrinsic and extrinsic mechanisms of immune resistance to immunotherapy.
RESULTS

T Cell Infiltrates Correlate with PRC2 Subunit Upregulation in Melanoma
Comparison of CD8 + T cell-associated genes (Bindea et al., 2013) with epigenetic modifier genes within The Cancer Genome Atlas (TCGA) human skin cutaneous melanoma (SKCM) RNAsequencing (RNA-seq) data (Cancer Genome Atlas Network, 2015) revealed a strong positive correlation of CD8 + T cell genes with PRC2 complex members EED, SUZ12, EZH2, and EZH1, as well as with HDAC1 and SETD2 ( Figure 1A ). Conversely, PRC1 members and all other tested epigenetic modifier genes did not correlate positively with CD8 + T cell genes. These data suggested that intratumoral CD8 + T cell accumulation might promote PRC2 upregulation in melanoma. To functionally investigate this hypothesis, we used two transplantable and one spontaneous melanoma model. (1) The highly proliferative B16-F10 murine melanoma cell line becomes visible and palpable 3-4 days after cutaneous injection to syngeneic C57BL/6 wild-type (WT) mice, and, after day 4, is difficult to control by IL-2cx immunotherapy or immune checkpoint inhibitors (Arenas-Ramirez et al., 2016; Krieg et al., 2010; Ueha et al., 2015) . (2) (Zingg et al., 2015) . (3) Nras Q61K Ink4a À/À mice spontaneously develop primary skin melanomas at 5-7 months of age (Shakhova et al., 2012; Zingg et al., 2015) . Similar to B16-F10, IL-2cx delays but does not prevent melanoma in Nras Q61K Ink4a À/À animals (Arenas- Ramirez et al., 2016) .
In all three melanoma models, immunotherapy by IL-2cx or anti-CTLA-4 mAb caused an increase in mRNA expression of the PRC2 members Eed, Ezh2, and Suz12 ( Figures 1B-1G ). In contrast, expression of Ezh1 and further key epigenetic modifiers were not changed by immunotherapy. Notably, in B16-F10 and RIM-3 tumor areas infiltrated by CD45 + leukocytes, higher Ezh2 levels were found in comparison to areas with little immune cell infiltrates ( Figures 1H-1J ), in agreement with the TCGA-SKCM data ( Figure 1A) .
In comparison to WT mice, in animals deficient in recombinase-activating gene 1 (Rag1 À/À ; thus devoid of T and B cells) or in mice lacking both T cell receptor (TCR) ab + and TCRgd + T cells (Tcrbd À/À ), IL-2cx immunotherapy failed to upregulate PRC2, particularly Ezh2, at the mRNA and protein levels ( Figures  1K, 1L , S1A, and S1B). Moreover, IL-2cx or anti-CTLA-4 treatment of B16-F10 or RIM-3 cells in vitro did not cause any significant upregulation of PRC2 ( Figure S1C ). Together, these data suggest that tumor-infiltrating T cells promote PRC2 upregulation in both human and mouse melanoma.
Ezh2 Promotes Melanoma Dedifferentiation and Loss of Immunogenicity
We next investigated whether immunotherapy-induced increase in Ezh2 resulted in enhanced Ezh2 activity. Indeed, IL-2cx or anti-CTLA-4 immunotherapy resulted in increased Ezh2 protein levels in B16-F10 and RIM-3 melanomas, which was accompanied by a global increase in H3K27me3 (Figures 2A-2C and S2A-S2E) . Of note, upon immunotherapy, H3K27me3 levels did not increase in B16-F10 tumors from Rag1 À/À or Tcrbd À/À mice (Figures S1A and S1B) . To study the molecular consequences of enhanced Ezh2 activity in melanoma cells, we sought to identify potential Ezh2 target genes (ETGs) associated with tumor cell immunogenicity. Immunotherapy of B16-F10 or RIM-3-harboring animals led to transcriptional silencing of a variety of presented as median ± 100% range of n = 5 from two independent experiments. p values were calculated using ANOVA and Fisher's least significant difference (LSD) (C-K) or unpaired Student's t tests (L). NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S1 .
genes, including members of major histocompatibility complex class I (MHC-I) molecules, antigen processing machinery, immunoproteasome, and several chemokines ( Figures 2D and S2F ). Furthermore, a set of melanocyte lineage genes (Denecker et al., 2014; Shakhova et al., 2012 ) was downregulated, some of which constitute known melanoma antigens (Dct and Pmel, also known as Trp2 and gp100). In contrast, expression of genes previously connected to melanoma dedifferentiation and epithelial-mesenchymal transition (EMT) (Caramel et al., 2013; Hö lzel and T€ uting, 2016; Shakhova et al., 2012) 2G , and S3A-S3D).
Ezh2 Inactivation Synergizes with Anti-melanoma Immunotherapy Our data suggested that Ezh2 inactivation was sufficient to reverse immunotherapy-induced immune resistance in melanoma. Indeed, compared to their monotherapies, a combination of IL-2cx and Ezh2 RNAi or anti-CTLA-4 and Ezh2 RNAi significantly delayed tumor growth, reducing tumor volume by over 75% ( Figures 3A-3C ). Similar effects were observed in mice harboring B16-F10 following administration of GSK503 combined with immunotherapy ( Figures 3D-3F ). Strikingly, co-administration of GSK503 and immunotherapy was also very efficient in Nras Q61K Ink4a À/À animals when treated at developing primary melanomas ( Figure 3G ). While the monotherapies showed some anti-tumor effects over PBS, the combination treatments were highly efficient in causing melanoma regression ( Figure 3H ). Consequently, at the time point of sacrifice, skin melanoma volumes and counts in mice receiving combination therapies were significantly reduced in comparison to monotherapies ( Figures 3H, 3I , and S3E), resulting in prolonged skinmelanoma-specific survival ( Figure 3J ). However, in mice with LLC1 Lewis lung carcinoma or MC-38 murine colon carcinoma, GSK503 + IL-2cx did not provide any advantage over , which correlated with the tumors' weak or absent upregulation of PRC2 members ( Figure S3H ).
Combination Therapy Stimulates CD8 + T Cells and
Suppresses the PD-1/PD-L1 Axis To assess the mechanism of action of immunotherapy combined with Ezh2 inhibition, we analyzed tumor-infiltrating lymphocytes p values were calculated using ANOVA and Fisher's LSD (B-I) or log-rank (Mantel-Cox) tests (J). NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S3 . CD44 high CD62L variable CD69 low with low expression of PD-1 and of other immune checkpoint molecules, such as T cell immunoglobulin and mucin domain-3 (TIM-3) and lymphocyte activation gene-3 (LAG-3) ( Figures 4D, 4E , S5E, and S5F). This suggested Ezh2 inhibition plus IL-2cx immunotherapy prevented intratumoral accumulation of exhausted CD8 + T cells.
Furthermore, immunotherapy promoted PD-L1 upregulation in melanomas ( Figures 4F, 4G , and S5G). Thus, Pax3
+ melanoma cells increased PD-L1 upon IL-2cx treatment, particularly in areas rich in CD3 + TILs ( Figures 4F and 4G ). This was consistent with the observed increase of Zeb1 upon immunotherapy (Figures S3C and S3D) , which has been shown to enhance PD-L1 expression (Chen et al., 2014) . Ezh2 inactivation, however, led to reduced PD-L1 mRNA levels and a decrease in PD-L1 Thus, during GSK503 + IL-2cx treatment, tumor control was lost in animals injected with anti-CD8 mAb, while mice receiving anti-CD4 mAb were able to suppress tumor growth ( Figure 5B ). The anti-tumor effect of GSK503 + IL-2cx depended on IFN-g production, as demonstrated using Ifng À/À mice ( Figure 5C ). In line with these data, high numbers of both CD90.1 À polyclonal CD8 + ( Figure 5D ) and, upon adoptive transfer, CD90.1 + Pmelspecific TCR-transgenic CD8 + T cells ( Figure 5E ) produced IFN-g when isolated from TDLNs of mice receiving IL-2cx or GSK503 + IL-2cx combination therapy, whereas IFN-g-producing cells were significantly lower in the other groups ( Figures 5D  and 5E ). Also, ex vivo cytotoxic activity of CD8 + T cells, as assessed by using the degranulation marker CD107a, was highest following combination immunotherapy, as shown by higher numbers of CD107a + CD8 + T cells within TILs from animals treated with Ezh2 blockade plus IL-2cx ( Figure 5F ).
In line with our observation that Ezh2 inactivation plus immunotherapy favored intratumoral accumulation of CD8 + T cells rather than their proliferation systemically or in TDLNs ( Figures  4B, S4A , and S5I), intratumoral expression of the T cell-attractant chemokines Cxcl9 and Cxcl10 increased upon Ezh2 inactivation ( Figure 5G ). In contrast, monoimmunotherapies resulted in PRC2-mediated silencing of Cxcl9 and Cxcl10 ( Figures 2D, 2E , 5G, S2F, and S2H). Accordingly, targeting of CXCR3, the receptor of the aforementioned chemokines, significantly reduced the anti-tumor effect of GSK503 + IL-2cx ( Figure 5H ).
TNF-a-Producing T Cells Cause PRC2-Mediated Melanoma Immune Resistance
Based on our findings, we reasoned that soluble factors released by the immune infiltrate might promote PRC2 gain of function in melanoma. To test this hypothesis, we applied a panel of growth factors and chemokines to B16-F10 and RIM-3 in vitro cultures. This screen revealed TNF-a to be the strongest factor in inducing upregulation of PRC2 subunits, whereas other prototypic proinflammatory cytokines only minimally upregulated or, in the case of IFN-g, even downregulated PRC2 members ( Figure 6A ). In contrast to IFN-g, inflammation and particularly production of TNF-a have previously been shown to promote melanoma dedifferentiation and tumor immune escape (Hö lzel and T€ uting, 2016) . Thus, we further investigated the relevance of TNF-a in PRC2-dependent melanoma immune evasion. TNF-a stimulation of B16-F10 cells induced Ezh2 expression and, consequently, led to increased H3K27me3 levels ( Figures 6B, 6C , and S6A). Moreover, exposure of B16-F10 and RIM-3 cells to TNF-a resulted in silencing of several antigen processing, presentation, and melanocyte lineage genes, as well as Cxcl9 and Cxcl10, in an Ezh2-dependent fashion ( Figures 6D and S6B ). This process inversely correlated with enrichment of H3K27me3 in the promoter regions of these genes ( Figures 6E and S6C) . The TNF-a-and Ezh2-dependent transcriptional changes appeared comparable to the gene expression changes observed in tumors upon immunotherapies (Figures 2 and S2) . Interestingly, B16-F10 and RIM-3 tumor lysates showed increased expression of Tnf mRNA and TNF-a protein when derived from animals receiving immunotherapy ( Figures 6F and 6G) . Similarly, Tnf expression was increased in tumors from Nras Q61K Ink4a
À/À mice treated with immunotherapy ( Figure 6H ). Tnf expression and TNF-a concentration in tumor nodules depended on the presence of T cells, as demonstrated using Rag1 À/À and Tcrbd À/À mice ( Figures 6I and 6J) . Furthermore, Tnf transcripts were nearly absent in B16-F10 tumors from Tnf À/À animals, suggesting that TNF-a was mostly released by host-derived cells rather than tumor cells ( Figure 6K ). Importantly, IL-2cx immunotherapy failed to upregulate PRC2 subunits, including Ezh2, in Tnf À/À mice ( Figure 6L ).
DISCUSSION
To better understand tumor resistance to immunotherapy, we investigated the role of the epigenetic modifier Ezh2 during anti-CTLA-4 and IL-2 treatment in models of aggressive melanoma. Our data demonstrate that immunotherapy led to increased Ezh2 activity that was dependent on T cells and TNF-a, resulting in melanoma dedifferentiation, loss of immunogenicity, and upregulation of the PD-1/PD-L1 axis. These findings fit and extend previous reports of immunotherapy using adoptive T cell transfer or activating T cells resulting in TNF-adependent melanoma dedifferentiation and PD-L1 upregulation (Hö lzel and T€ uting, 2016; Spranger et al., 2013) . Moreover, increased expression of the melanoma dedifferentiation gene Zeb1, as seen here upon immunotherapy, has been associated with enhanced PD-L1 expression (Chen et al., 2014; Wang et al., 2014) . However, these changes proved to be dynamic and malleable, in that inhibition of Ezh2 restored presentation of several dominant melanoma antigens while downregulating PD-L1 on melanoma cells. In parallel, PD-1 expression on tumor-antigenspecific and polyclonal melanoma-infiltrating CD8 + T cells decreased significantly, thus improving effector functions of the cells, including IFN-g production and cytotoxicity. The net result of these effects was control of melanoma growth and, in the case of Nras Q61K Ink4a À/À mice, tumor regression, which clearly exceeded the efficacy of monotherapies consisting of IL-2cx, anti-CTLA-4, or Ezh2 inhibition (Arenas-Ramirez et al., 2016; Krieg et al., 2010; Ueha et al., 2015; Zingg et al., 2015) . Unlike melanoma, mice carrying LLC1 Lewis lung carcinoma or MC-38 murine colon carcinoma showed barely any upregulation of Ezh2 upon immunotherapy. Consequently, these cancer models did not benefit from the addition of Ezh2 blockade to immunotherapy, pointing to a melanoma-specific role of PRC2 in governing immune evasion. Recent reports suggested a somewhat antagonistic role of PRC2 in the anti-tumor immune response (Peng et al., 2015; Zhao et al., 2016) . In ovarian and colon cancer cells, PRC2 was able to repress CD8 + T cell trafficking to the tumor site (Nagarsheth et al., 2016; Peng et al., 2015) . Consistent with these data we found that upon Ezh2 inactivation, effector CD8 + T cells preferentially accumulated intratumorally in a CXCL9/CXCL10-CXCR3-dependent fashion. Moreover, we complement these findings by demonstrating that T cell-and TNF-a-dependent Ezh2 upregulation is implicated in several other immune escape mechanisms, namely melanoma dedifferentiation, tumor cell immunogenicity, and the PD-1/PD-L1 axis. Thus, Ezh2 inactivation locks melanoma cells in an immunogenic state and facilitates efficient CD8 + T cell-mediated anti-tumor responses during immunotherapy. However, Ezh2 has also been shown to affect T cells directly by improving survival and activity of anti-tumor CD8 + T cells and maintaining Foxp3 + Treg cells (DuPage et al., 2015) . In our study, however, melanoma cell-specific Ezh2 RNAi led to similar effects as systemic Ezh2
blockade. Furthermore, despite systemic Ezh2 inhibition, we did not find any evidence for compromised CD8 + T cell function in our melanoma models, while Foxp3 + Treg cells failed to accumulate within TILs. Hence, this discrepancy might be due to the tumor models or immunotherapies used in the different studies. High EZH2 expression is associated with unfavorable prognosis in human cutaneous melanoma, and Ezh2 inactivation antagonizes metastatic progression in murine melanoma models (Manning et al., 2015; Zingg et al., 2015) . Moreover, in several cancers, tumor stemness and EMT have been linked to immune evasion (Hö lzel and T€ uting, 2016; Lou et al., 2016; Tripathi et al., 2016) . Finally, tumor biopsy specimens from cutaneous melanoma patients displaying resistance to checkpoint blockade therapy showed increased expression of melanoma dedifferentiation genes in favor of melanocyte lineage genes (Hugo et al., 2016) . Hence, melanoma might similarly take advantage of PRC2 activity to promote EMT, resulting in resistance to immune pressure during T cell-engaging immunotherapy and ultimately metastasis.
Despite some long-term responders, a notable number of melanoma patients are intrinsically resistant to PD-1/PD-L1 checkpoint blockade, for instance due to a paucity of PD-1 + TILs or of PD-L1 expression on tumor cells (Herbst et al., 2014; Hugo et al., 2016; Tumeh et al., 2014; Van Allen et al., 2015) . Since blockade of Ezh2 is associated with downregulation of the PD-1/PD-L1 axis and, therefore, independent of PD-1 and PD-L1 expression levels in patients, the combination therapies presented here might offer an alternative strategy for patients resistant to anti-PD-1 and anti-PD-L1 treatment.
EZH2 inhibitors are currently tested in several clinical trials in solid and hematological malignancies with the aim of exerting an antiproliferative effect on the cancer cells (Kim and Roberts, 2016) . Our data suggest that subtoxic doses of EZH2 inhibitors might suffice to prevent cancer immune resistance during immunotherapy. Hence, targeting of EZH2 is an attractive strategy to combine with cancer immunotherapy.
EXPERIMENTAL PROCEDURES
Mice 3-month-old female C57BL/6 mice were purchased from Charles River Laboratories. Tcrbd ) transgenic mice on a mixed background were mated, genotyped, and monitored for tumor development as described previously (Zingg et al., 2015) . Tumor volume was calculated as described previously (Arenas-Ramirez (F and G) Immunofluorescence staining for Pax3, PD-L1, and CD3 in RIM-3 (F) from mice treated as in Figure 3D , and quantification of Pax3 + PD-L1 + cells in areas poor or rich in CD3 + cells (CD3 + n < 5 versus n > 20 per field) (G). Scale bars, 50 mm.
(H) Tumor growth kinetics in mice engrafted with RIM-3 cells and receiving PBS, IL-2cx, PD-1-blocking antibody (a-PD-1), or GSK503 as indicated. Black arrows mark the time point when treatment started. Data are presented as mean ± SEM of n = 4-6 (B and C, TILs), n = 16-17 (B and C, TDLNs), and n = 5 (E-H) from six (A-C), two (D), and five (E) independent experiments or one experiment (G and H). For TILs, samples of mice receiving the same treatment were pooled prior to analysis. p values were calculated using an unpaired Student's t test (B, and percentages in E) or ANOVA and the Fisher's LSD test (G and H). NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figures S4 and S5 . (D and E) Mice were adoptively transferred with CD90.1 + Pmel-specific T cell-receptor-transgenic CD8 + T cells, followed by treatment as in Figure 3D . Shown is IFN-g production and quantification of IFN-g + cells within CD90.1 À polyclonal (D) versus CD90.1 + Pmel-specific (E) CD8 + T cells from TDLNs.
(F) Mice were treated as in Figure 3D , followed by assessment of intratumoral CD107a + CD8 + T cells per cubic millimeter of tumor.
(G) qRT-PCR for Cxcl9 and Cxcl10 in shCo-or shEzh2-transfected B16-F10 melanoma nodules from mice receiving PBS, IL-2cx, or a-CTLA-4. (H) Tumor growth kinetics in B16-F10-bearing mice receiving PBS, GSK503 + IL-2cx, or GSK503 + IL-2cx plus CXCR3-blocking antibody (a-CXCR3). Black and red arrows indicate the time point of treatment start and mAb injection, respectively. Data are presented as mean ± SEM of n = 8 (A), n = 6 (B), n = 7-9 (C), n = 8-13 (D), n = 7-13 (E), n = 2 (F), and n = 9 (H) and as median ± 100% range of n = 5-8 (G) from two (A-F and H) and three (G) independent experiments. p values were calculated using ANOVA and Bonferroni correction (A-C and H), the Fisher's LSD test (G), or an unpaired Student's t test (D-F). NS, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. et al., 2016). Skin-melanoma-specific survival of Nras Q61K Ink4a À/À mice was considered melanoma independent (censored event), when at the time point of sacrifice more than 50% of skin melanomas showed a tumor volume reduction greater than 50%. Animal experiments were approved by the veterinary authorities of Canton of Zurich, Switzerland, and were performed in accordance with Swiss law and GlaxoSmithKline policy on the Care, Welfare, and Treatment of Animals. Pre-established exclusion criteria were based on the Canton of Zurich veterinary authority's guidelines and included substantial weight loss of Dm >15% of initial body weight.
Cell Cultures
The murine B16-F10 (CRL-6475, ATCC), LLC1, and MC-38 (provided by R. Schwendener) cell lines were cultured in growth medium. RIM-3 skin melanoma cells derived from a Nras Q61K Ink4a À/À mouse on a pure C57BL/6 background (Zingg et al., 2015) were cultured on plates coated with fibronectin (F1141, Sigma-Aldrich) using melanocyte medium, which was DMEM/F-12 (21041, Thermo Fisher Scientific) supplemented with 10% fetal calf serum (FCS), penicillin-streptomycin, and 200 nM phorbol 12-myristate 13-acetate (PMA; P1585, Sigma-Aldrich).
Adoptive Tumor Models Recipient mice were intradermally or subcutaneously engrafted with either 500,000 RIM-3 cells or 1 3 10 6 B16-F10, LLC1, or MC-38 cells. Mice were sacrificed either at indicated time points or upon reaching a maximal tumor volume of V = 2,000 mm 3 . + cells using 500 mg anti-CD8 mAb (a-CD8, clone YTS169, BioXcell), and CXCR3 using 500 mg a-CXCR3 mAb. Depleting mAbs were administered i.p. every other day (a-CD4 and a-CD8) or every 3 days (a-CXCR3) starting on day 0 of tumor implantation until the end of the experiment. Where indicated, CD90.1 + Pmel-specific CD8 + T cells were obtained as established previously (Arenas-Ramirez et al., 2016) from Pmel Si Thy1 a transgenic mice. At least 2 3 10 6 purified and carboxyfluorescein succinimidyl ester (CFSE; Thermo
In Vivo Treatments
Fisher Scientific)-labeled CD8 + T cells were adoptively transferred to recipients. Cell proliferation was measured using bromodeoxyuridine (BrdU; B5002, Sigma-Aldrich) as described previously (Arenas-Ramirez et al., 2016) .
Flow Cytometry
Single-cell suspensions of lymph nodes, spleen, and tumors were prepared and stained as previously described (Arenas-Ramirez et al., 2016) . Fluorochrome-conjugated antibodies are listed in Table S1 . Intracellular CD107a, FoxP3, and IFN-g staining was performed following the manufacturers' instructions after in vitro restimulation using PMA and ionomycin (0.1 mg/mL and 1 mg/mL, P8139 and I0634, Sigma-Aldrich) in the presence of brefeldin A and monensin (2 mg/mL, B7651 and M5273, Sigma-Aldrich).
Samples were acquired with a BD LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software.
Histological Analysis and Immunofluorescence
For immunofluorescence staining, mouse tumor samples were processed and stained as established (O'Connell et al., 2013; Zingg et al., 2015) using primary and secondary antibodies (Tables S2 and S3 ). Sections were recorded using a DMI 6000B microscope (Leica). Images were processed by Photoshop CS5 software (Adobe) to exclude areas covered by CD45 or CD3 staining. To measure cytoplasmic Pmel labeling, brightness of the Pmel signal was measured with CellProfiler software (Carpenter et al., 2006 ) (MeasureImageIntensity). To measure nuclear staining (Ezh2, Mitf, Zeb1), algorithms in CellProfiler identifying nuclei (IdentifyPrimaryObjects) and quantifying nuclear intensities (MeasureObjectIntensity) were applied. CD45 + or Pax3 + PD-L1 + cells were counted manually. For each tumor, at least ten fields containing either n < 5 or n > 20 CD45 + or CD3 + cells were quantified.
In Vitro Silencing and Inhibition of Ezh2
To stably silence Ezh2, B16-F10 cells were transfected with small hairpin RNA (shRNA)-expressing plasmids encoding either a scrambled shRNA (shCo; SHC002, Sigma-Aldrich) or Ezh2 mRNA-targeting shRNA (shEzh2; TRCN0000039040, Sigma-Aldrich). 10 mg plasmid was applied in combination with jetPEI DNA Transfection Reagent (101-10N, Polyplus Transfection) according to the manufacturer's recommendations. Transfected cells were selected using 1 mg/mL puromycin (A11138-02, Life Technologies) for 1 week before further assessment. To pharmacologically inhibit Ezh2, cells were treated with 1 mM GSK503 for 8 days before further assessment. Efficiency of shEzh2 and GSK503 has been validated previously (Zingg et al., 2015) .
In Vitro Growth Factor and Chemokine Treatments Growth factors and chemokines indicated in Table S4 were resolved in 0.1% BSA in PBS. Cells were grown in starvation medium (1% FCS) for 48 hr and subsequently treated with growth factors and chemokines, 1000 U/mL Data are presented as mean of n = 3 (A, D, and E), mean ± SEM of n = 3 (B and C), n = 20 tumors of eight mice (H, PBS), n = 26 tumors of nine mice (H, IL-2cx), and n = 22 tumors of ten mice (H, a-CTLA-4) and median ± 100% range of n = 5-8 (F, B16-F10, K, and L), n = 4 (F, RIM-3, I, and J), n = 9 (G, B16-F10), and n = 7 (G, RIM-3) from three (A-G), one (H), or two (I-L) independent experiments. p values were calculated using ANOVA and the Fisher's LSD test. NS, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S6 .
IL-2cx or 16.7 mg/mL a-CTLA-4 for 48 hr in starvation medium before further assessment. Table S5 . Relative quantified RNA was normalized using Usf1 as housekeeping transcript.
RNA Isolation and qRT-PCR
Chromatin Isolation and ChIP
Chromatin isolation and ChIP of cultured cells and tumor nodules was performed according to the manufacturer's guidelines using the SimpleChIP Plus Enzymatic Chromatin IP Kit (9005, Cell Signaling Technology). Briefly, 10 7 cultured cells were crosslinked on culture plates and subjected to chromatin isolation, while tumor samples of 150 mg were minced using scissors prior to crosslinking. Crosslinked samples were disaggregated into single cells using a Polytron PT 2100 tissue disperser. Isolated nuclei were digested with 5 mL micrococcal nuclease for 30 min at 37 C, and nuclei were lysed using a SONOPULS HD 2070 Ultrasonic Homogenizer (Bandelin). ChIP was performed with 18 mg chromatin and the primary antibodies listed in Table S2 . qPCR was performed on a LightCycler 480 System using the KAPA SYBR Fast qPCR Kit Master Mix (KR0389, KAPA Biosystems). Primers were specified to amplify genomic DNA from a region flanking the transcriptional starting site À500 bp to +100 bp devoid of local CpG islands, and are indicated in Table S6 . Relative promoter enrichment was normalized to chromatin inputs, and the intergenic region 1 (Interg1) was used as negative control.
Protein Isolation and Western Blotting
Protein lysates of cultured cells and tumor nodules were isolated and western blots performed as described previously (Zingg et al., 2015) . Briefly, SDS-PAGE was carried out on 4%-20% Mini-PROTEAN TGX Gels (456-1094, Bio-Rad). Primary antibodies (Table S2) were applied in Odyssey blocking buffer (927-40000, LI-COR Biosciences) overnight at 4 C and visualized using secondary antibodies (Table S3) in Odyssey blocking buffer for 45 min at room temperature. Blots were scanned and quantified with an Odyssey imaging system (LI-COR Biosciences). Quantified band intensities were normalized using either b-actin or histone 3 as housekeeping protein.
ELISA 4 mg/mL protein lysate isolated as for western blotting was subjected to the Mouse TNF-alpha Quantikine ELISA Kit (MTA00B, R&D Systems) according to the manufacturer's protocol. Optical density was measured using a DTX 880 Multimode Detector (Beckman Coulter) at 450 nm.
Gene Expression Correlation Analyses
The RNA-seq dataset for SKCM was downloaded from TCGA data portal (Cancer Genome Atlas Network, 2015) . RSEM normalized RNA-seq reads were used for differential RNA expression analysis using R software. Genes indicative of presence of intratumoral CD8 + T cells have previously been defined (Bindea et al., 2013) . Within the TCGA-SKCM RNA-seq dataset, expression of each of these CD8 + T cell signature genes was correlated to the expression of epigenetic modifier genes. Significance of correlative gene expression was calculated by using Pearson's product-moment correlation coefficient (r). 
Statistical Analyses
